Antibody data
- Antibody Data
- Antigen structure
- References [18]
- Comments [0]
- Validations
- Western blot [3]
- Immunoprecipitation [1]
- Immunohistochemistry [2]
Submit
Validation data
Reference
Comment
Report error
- Product number
- NB200-331 - Provider product page
- Provider
- Novus Biologicals
- Proper citation
- Novus Cat#NB200-331, RRID:AB_2283605
- Product name
- Rabbit Polyclonal PELP1 Antibody
- Antibody type
- Polyclonal
- Description
- Immunogen affinity purified.
- Reactivity
- Human, Mouse
- Host
- Rabbit
- Isotype
- IgG
- Vial size
- 100 ul
- Concentration
- 1.0 mg/ml
- Storage
- Store at 4C. Do not freeze.
Submitted references Breast Tumor Kinase (Brk/PTK6) Is Induced by HIF, Glucocorticoid Receptor, and PELP1-Mediated Stress Signaling in Triple-Negative Breast Cancer.
Targeting the PELP1-KDM1 axis as a potential therapeutic strategy for breast cancer.
Therapeutic targeting of PELP1 prevents ovarian cancer growth and metastasis.
Cyclin-dependent kinase-mediated phosphorylation plays a critical role in the oncogenic functions of PELP1.
MNAR functionally interacts with both NH2- and COOH-terminal GR domains to modulate transactivation.
Growth factor regulation of estrogen receptor coregulator PELP1 functions via Protein Kinase A pathway.
The nutritional flavanone naringenin triggers antiestrogenic effects by regulating estrogen receptor alpha-palmitoylation.
Modulation of in situ estrogen synthesis by proline-, glutamic acid-, and leucine-rich protein-1: potential estrogen receptor autocrine signaling loop in breast cancer cells.
Role of PELP1/MNAR signaling in ovarian tumorigenesis.
Identifying the estrogen receptor coactivator PELP1 in autophagosomes.
Phosphorylation of MNAR promotes estrogen activation of phosphatidylinositol 3-kinase.
Proline-, glutamic acid-, and leucine-rich protein-1/modulator of nongenomic activity of estrogen receptor enhances androgen receptor functions through LIM-only coactivator, four-and-a-half LIM-only protein 2.
Oncogenic potential of the nuclear receptor coregulator proline-, glutamic acid-, leucine-rich protein 1/modulator of the nongenomic actions of the estrogen receptor.
Estrogen receptor signaling pathways in human non-small cell lung cancer.
Long-term treatment with tamoxifen facilitates translocation of estrogen receptor alpha out of the nucleus and enhances its interaction with EGFR in MCF-7 breast cancer cells.
Characterization of MNAR expression.
Steroid receptor regulation of epidermal growth factor signaling through Src in breast and prostate cancer cells: steroid antagonist action.
Cloning, expression, and localization of MNAR/PELP1 in rodent brain: colocalization in estrogen receptor-alpha- but not in gonadotropin-releasing hormone-positive neurons.
Regan Anderson TM, Ma SH, Raj GV, Cidlowski JA, Helle TM, Knutson TP, Krutilina RI, Seagroves TN, Lange CA
Cancer research 2016 Mar 15;76(6):1653-63
Cancer research 2016 Mar 15;76(6):1653-63
Targeting the PELP1-KDM1 axis as a potential therapeutic strategy for breast cancer.
Cortez V, Mann M, Tekmal S, Suzuki T, Miyata N, Rodriguez-Aguayo C, Lopez-Berestein G, Sood AK, Vadlamudi RK
Breast cancer research : BCR 2012 Jul 19;14(4):R108
Breast cancer research : BCR 2012 Jul 19;14(4):R108
Therapeutic targeting of PELP1 prevents ovarian cancer growth and metastasis.
Chakravarty D, Roy SS, Babu CR, Dandamudi R, Curiel TJ, Vivas-Mejia P, Lopez-Berestein G, Sood AK, Vadlamudi RK
Clinical cancer research : an official journal of the American Association for Cancer Research 2011 Apr 15;17(8):2250-9
Clinical cancer research : an official journal of the American Association for Cancer Research 2011 Apr 15;17(8):2250-9
Cyclin-dependent kinase-mediated phosphorylation plays a critical role in the oncogenic functions of PELP1.
Nair BC, Nair SS, Chakravarty D, Challa R, Manavathi B, Yew PR, Kumar R, Tekmal RR, Vadlamudi RK
Cancer research 2010 Sep 15;70(18):7166-75
Cancer research 2010 Sep 15;70(18):7166-75
MNAR functionally interacts with both NH2- and COOH-terminal GR domains to modulate transactivation.
Kayahara M, Ohanian J, Ohanian V, Berry A, Vadlamudi R, Ray DW
American journal of physiology. Endocrinology and metabolism 2008 Nov;295(5):E1047-55
American journal of physiology. Endocrinology and metabolism 2008 Nov;295(5):E1047-55
Growth factor regulation of estrogen receptor coregulator PELP1 functions via Protein Kinase A pathway.
Nagpal JK, Nair S, Chakravarty D, Rajhans R, Pothana S, Brann DW, Tekmal RR, Vadlamudi RK
Molecular cancer research : MCR 2008 May;6(5):851-61
Molecular cancer research : MCR 2008 May;6(5):851-61
The nutritional flavanone naringenin triggers antiestrogenic effects by regulating estrogen receptor alpha-palmitoylation.
Galluzzo P, Ascenzi P, Bulzomi P, Marino M
Endocrinology 2008 May;149(5):2567-75
Endocrinology 2008 May;149(5):2567-75
Modulation of in situ estrogen synthesis by proline-, glutamic acid-, and leucine-rich protein-1: potential estrogen receptor autocrine signaling loop in breast cancer cells.
Rajhans R, Nair HB, Nair SS, Cortez V, Ikuko K, Kirma NB, Zhou D, Holden AE, Brann DW, Chen S, Tekmal RR, Vadlamudi RK
Molecular endocrinology (Baltimore, Md.) 2008 Mar;22(3):649-64
Molecular endocrinology (Baltimore, Md.) 2008 Mar;22(3):649-64
Role of PELP1/MNAR signaling in ovarian tumorigenesis.
Dimple C, Nair SS, Rajhans R, Pitcheswara PR, Liu J, Balasenthil S, Le XF, Burow ME, Auersperg N, Tekmal RR, Broaddus RR, Vadlamudi RK
Cancer research 2008 Jun 15;68(12):4902-9
Cancer research 2008 Jun 15;68(12):4902-9
Identifying the estrogen receptor coactivator PELP1 in autophagosomes.
Ohshiro K, Rayala SK, Kondo S, Gaur A, Vadlamudi RK, El-Naggar AK, Kumar R
Cancer research 2007 Sep 1;67(17):8164-71
Cancer research 2007 Sep 1;67(17):8164-71
Phosphorylation of MNAR promotes estrogen activation of phosphatidylinositol 3-kinase.
Greger JG, Fursov N, Cooch N, McLarney S, Freedman LP, Edwards DP, Cheskis BJ
Molecular and cellular biology 2007 Mar;27(5):1904-13
Molecular and cellular biology 2007 Mar;27(5):1904-13
Proline-, glutamic acid-, and leucine-rich protein-1/modulator of nongenomic activity of estrogen receptor enhances androgen receptor functions through LIM-only coactivator, four-and-a-half LIM-only protein 2.
Nair SS, Guo Z, Mueller JM, Koochekpour S, Qiu Y, Tekmal RR, Schüle R, Kung HJ, Kumar R, Vadlamudi RK
Molecular endocrinology (Baltimore, Md.) 2007 Mar;21(3):613-24
Molecular endocrinology (Baltimore, Md.) 2007 Mar;21(3):613-24
Oncogenic potential of the nuclear receptor coregulator proline-, glutamic acid-, leucine-rich protein 1/modulator of the nongenomic actions of the estrogen receptor.
Rajhans R, Nair S, Holden AH, Kumar R, Tekmal RR, Vadlamudi RK
Cancer research 2007 Jun 1;67(11):5505-12
Cancer research 2007 Jun 1;67(11):5505-12
Estrogen receptor signaling pathways in human non-small cell lung cancer.
Márquez-Garbán DC, Chen HW, Fishbein MC, Goodglick L, Pietras RJ
Steroids 2007 Feb;72(2):135-43
Steroids 2007 Feb;72(2):135-43
Long-term treatment with tamoxifen facilitates translocation of estrogen receptor alpha out of the nucleus and enhances its interaction with EGFR in MCF-7 breast cancer cells.
Fan P, Wang J, Santen RJ, Yue W
Cancer research 2007 Feb 1;67(3):1352-60
Cancer research 2007 Feb 1;67(3):1352-60
Characterization of MNAR expression.
Greger JG, Guo Y, Henderson R, Ross JF, Cheskis BJ
Steroids 2006 Apr;71(4):317-22
Steroids 2006 Apr;71(4):317-22
Steroid receptor regulation of epidermal growth factor signaling through Src in breast and prostate cancer cells: steroid antagonist action.
Migliaccio A, Di Domenico M, Castoria G, Nanayakkara M, Lombardi M, de Falco A, Bilancio A, Varricchio L, Ciociola A, Auricchio F
Cancer research 2005 Nov 15;65(22):10585-93
Cancer research 2005 Nov 15;65(22):10585-93
Cloning, expression, and localization of MNAR/PELP1 in rodent brain: colocalization in estrogen receptor-alpha- but not in gonadotropin-releasing hormone-positive neurons.
Khan MM, Hadman M, Wakade C, De Sevilla LM, Dhandapani KM, Mahesh VB, Vadlamudi RK, Brann DW
Endocrinology 2005 Dec;146(12):5215-27
Endocrinology 2005 Dec;146(12):5215-27
No comments: Submit comment
Supportive validation
- Submitted by
- Novus Biologicals (provider)
- Main image
- Experimental details
- Western Blot: PELP1 Antibody [NB200-331] - Samples: Whole cell lysate (5, 15 and 50 ug for WB; 1 mg for IP, 20% of IP loaded) from HeLa cells. Antibodies: Affinity purified rabbit anti-PELP1 antibody NB200-331 lot number 2 used for WB at 0.04 ug/ml (A) and 1 ug/ml (B) and used for IP at 3 ug/mg lysate (B). PELP1 was also immunoprecipitated by previous lot 1 of this antibody. Detection: Chemiluminescence with exposure times of 10 second (A) and 3 seconds (B).
- Submitted by
- Novus Biologicals (provider)
- Main image
- Experimental details
- Western Blot: PELP1 Antibody [NB200-331] - Detection of Human PELP1/MNAR by Western Blot. Samples: Whole cell lysate (50 ug) from HeLa and 293T cells prepared using NETN lysis buffer. Antibody: Affinity purified rabbit anti-PELP1/MNAR antibody NB200-331 used for WB at 0.4 ug/ml. Detection: Chemiluminescence with an exposure time of 3 seconds.
- Submitted by
- Novus Biologicals (provider)
- Main image
- Experimental details
- Western Blot: PELP1 Antibody [NB200-331] - Detection of mouse PELP1/MNAR by western blot. Samples: Whole cell lysate (50 ug) from NIH 3T3 cells prepared using NETN lysis buffer. Antibody: Affinity purified rabbit anti-PELP1/MNAR antibody NB200-331 used for WB at 0.4 ug/ml. Detection: Chemiluminescence with an exposure time of 10 seconds.
Supportive validation
- Submitted by
- Novus Biologicals (provider)
- Main image
- Experimental details
- Immunoprecipitation: PELP1 Antibody [NB200-331] - Detection of human PELP1/MNAR by western blot of immunoprecipitates. Samples: Whole cell lysate (0.5 or 1.0 mg per IP reaction; 20% of IP loaded) from HeLa cells prepared using NETN lysis buffer. Antibodies: Affinity purified rabbit anti-PELP1/MNAR antibody NB200-331 (lot NB200-331-3) used for IP at 6 ug per reaction. PELP1/MNAR was also immunoprecipitated by a previous lot of this antibody (lot NB200-331-2) and rabbit anti-PELP1/MNAR antibody NB110-40622. For blotting immunoprecipitated PELP1/MNAR, NB200-331 was used at 0.4 ug/ml. Detection: Chemiluminescence with an exposure time of 1 second.
Supportive validation
- Submitted by
- Novus Biologicals (provider)
- Main image
- Experimental details
- Immunohistochemistry: PELP1 Antibody [NB200-331] - Samples: FFPE sections of mouse renal cell carcinoma.~ Antibodies: Affinity purified rabbit anti-PELP1/MNAR ~Cat. No. Lot2 used at a dilution of 1:2,500 (0.4ug/ml) (left) and Cat. No. Lot3 used at a dilution of 1:5,000 (0.2ug/ml) (right). Detection: DAB.
- Submitted by
- Novus Biologicals (provider)
- Main image
- Experimental details
- Immunohistochemistry: PELP1 Antibody [NB200-331] - Samples: FFPE sections of human ovarian carcinoma.~ Antibodies: Affinity purified rabbit anti-PELP1/MNAR ~Cat. No. Lot2 used at a dilution of 1:2,500 (0.4ug/ml) (left) and Cat. No. Lot3 used at a dilution of 1:5,000 (0.2ug/ml) (right). Detection: DAB.